ALK and non-small cell lung carcinoma: Cemiplimab is approved in Europe as a first-line therapy of locally advanced or metastatic low-(≥1%) or high-PD-L1 (≥50% TPS) NSCLC without EGFR, ALK, or ROS aberrations and only when not indicated for definitive radiochemotherapy [19].